Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy

Annals of Oncology

Volumn 21, Issue 11, 2010, Pages 2278-2283

  Passero, V A ^a   Branstetter, B F ^a   Shuai, Y ^a   Heron, D E ^b   Gibson, M K ^a   Lai, S Y ^a,c   Kim, S W ^a   Grandis, J R ^a   Ferris, R L ^a   Johnson, J T ^a   Argiris, A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiotherapy; Head and neck cancer; Objective response; PET CT; RECIST

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77958481883     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq226     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371: 1695-1709.
3. Pignon JP, le Maitre A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69: S112-S114.
4. Leemans CR, Tiwari R, Nauta JJ et al. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73: 187-190.
5. Ritoe SC, Krabbe PF, Kaanders JH et al. Value of routine follow-up for patients cured of laryngeal carcinoma. Cancer 2004; 101: 1382-1389.
6. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
7. Lowe VJ, Boyd JH, Dunphy FR et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18: 651-658.
8. Branstetter BF, Blodgett TM, Zimmer LA et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005; 235: 580-586.
9. Nayak JV, Walvekar RR, Andrade RS et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PETCT. Laryngoscope 2007; 117: 2129-2134.
10. Yao M, Smith RB, Graham MM et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005; 63: 991-999.
11. Andrade RS, Heron DE, Degirmenci B et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006; 65: 1315-1322.
12. Agarwal V, Branstetter BF, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am 2008; 41: 23-49, v.
13. Shankar LK, Hoffman JM, Bacharach S et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: 1059-1066.
14. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In Survival Analysis, 2nd edition. New York: Springer 2005; 243-287.
15. Gordin A, Daitzchman M, Doweck I et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope 2006; 116: 273-278.
16. Gordin A, Golz A, Keidar Z et al. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg 2007; 137: 130-137.
17. Zimmer LA, Snyderman C, Fukui MB et al. The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience. Ear Nose Throat J 2005; 84: 104, 106, 108-110.
18. Connell CA, Corry J, Milner AD et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007; 29: 986-995.
19. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
20. Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005; 115: 645-650.
21. Greven KM, Williams DW, III, McGuirt WF, Sr et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23: 942-946.
22. Ong SC, Schoder H, Lee NY et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-540.
23. Moeller BJ, Rana V, Cannon BA et al. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009; 27: 2509-2515.